These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30143046)

  • 1. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.
    Sadowski AR; Gardner HL; Borgatti A; Wilson H; Vail DM; Lachowicz J; Manley C; Turner A; Klein MK; Waite A; Sahora A; London CA
    BMC Vet Res; 2018 Aug; 14(1):250. PubMed ID: 30143046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
    London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
    PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
    Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
    BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.
    Grayton JE; Miller T; Wilson-Robles H
    Vet Comp Oncol; 2017 Dec; 15(4):1455-1467. PubMed ID: 28133930
    [No Abstract]   [Full Text] [Related]  

  • 5. The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.
    Breitbach JT; Louke DS; Tobin SJ; Watts MR; Davies AE; Fenger JM
    Vet Comp Oncol; 2021 Jun; 19(2):362-373. PubMed ID: 33438820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
    Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
    Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Nuclear Attack on Traumatic Brain Injury: Sequestration of Cell Death in the Nucleus.
    Tajiri N; De La Peña I; Acosta SA; Kaneko Y; Tamir S; Landesman Y; Carlson R; Shacham S; Borlongan CV
    CNS Neurosci Ther; 2016 Apr; 22(4):306-15. PubMed ID: 26842647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
    Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
    Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
    [No Abstract]   [Full Text] [Related]  

  • 9. Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.
    Pickens JA; Tripp RA
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29361733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
    Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
    Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
    BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
    Ben-Barouch S; Kuruvilla J
    Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
    [No Abstract]   [Full Text] [Related]  

  • 13. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.
    Etchin J; Berezovskaya A; Conway AS; Galinsky IA; Stone RM; Baloglu E; Senapedis W; Landesman Y; Kauffman M; Shacham S; Wang JC; Look AT
    Leukemia; 2017 Jan; 31(1):143-150. PubMed ID: 27211268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
    Gounder MM; Zer A; Tap WD; Salah S; Dickson MA; Gupta AA; Keohan ML; Loong HH; D'Angelo SP; Baker S; Condy M; Nyquist-Schultz K; Tanner L; Erinjeri JP; Jasmine FH; Friedlander S; Carlson R; Unger TJ; Saint-Martin JR; Rashal T; Ellis J; Kauffman M; Shacham S; Schwartz GK; Abdul Razak AR
    J Clin Oncol; 2016 Sep; 34(26):3166-74. PubMed ID: 27458288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
    Shafique M; Ismail-Khan R; Extermann M; Sullivan D; Goodridge D; Boulware D; Hogue D; Soliman H; Khong H; Han HS
    Oncologist; 2019 Jul; 24(7):887-e416. PubMed ID: 30996012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
    Harrington BK; Gardner HL; Izumi R; Hamdy A; Rothbaum W; Coombes KR; Covey T; Kaptein A; Gulrajani M; Van Lith B; Krejsa C; Coss CC; Russell DS; Zhang X; Urie BK; London CA; Byrd JC; Johnson AJ; Kisseberth WC
    PLoS One; 2016; 11(7):e0159607. PubMed ID: 27434128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
    Thamm DH; Vail DM; Post GS; Fan TM; Phillips BS; Axiak-Bechtel S; Elmslie RS; Klein MK; Ruslander DA
    J Vet Intern Med; 2017 May; 31(3):872-878. PubMed ID: 28370378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor.
    Pan L; Cheng C; Duan P; Chen K; Wu Y; Wu Z
    J Exp Clin Cancer Res; 2021 Aug; 40(1):255. PubMed ID: 34384466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma.
    Gardner HL; Rippy SB; Bear MD; Cronin KL; Heeb H; Burr H; Cannon CM; Penmetsa KV; Viswanadha S; Vakkalanka S; London CA
    PLoS One; 2018; 13(4):e0195357. PubMed ID: 29689086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.